HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peter Pertel Selected Research

Peter Pertel Research Topics

Disease

3Infections
10/2021 - 11/2005
3Malaria
10/2021 - 10/2014
3Diarrhea
03/2015 - 11/2012
2Clostridium Infections
03/2015 - 03/2015
1Parasitic Diseases (Parasitic Disease)
10/2021
1Hypersensitivity (Allergy)
01/2016
1Falciparum Malaria (Plasmodium falciparum Malaria)
01/2016
1Vivax Malaria
01/2016
1Hematoma
10/2014
1Dizziness (Lightheadedness)
10/2014
1Headache (Headaches)
10/2014
1Nausea
10/2014
1Community-Acquired Infections
08/2006
1Intraabdominal Infections
08/2006
1Sinusitis
04/2006
1Maxillary Sinusitis
04/2006

Drug/Important Bio-Agent (IBA)

3ganaplacideIBA
10/2021 - 11/2014
3LFF571IBA
03/2015 - 11/2012
3Moxifloxacin (Avelox)FDA Link
08/2006 - 11/2005
2Antimalarials (Antimalarial Agents)IBA
01/2016 - 11/2014
2VancomycinFDA LinkGeneric
03/2015 - 03/2015
2Clavulanic Acid (Potassium Clavulanate)FDA LinkGeneric
08/2006 - 11/2005
2Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric
08/2006 - 11/2005
2Amoxicillin (Wymox)FDA LinkGeneric
08/2006 - 11/2005
1proguanil drug combination atovaquone (malarone)FDA Link
10/2021
11- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)IBA
10/2021
1AntibodiesIBA
01/2016
1NITD 609IBA
10/2014

Therapy/Procedure

2Therapeutics
03/2015 - 04/2006
1Aftercare (After-Treatment)
01/2016
1Catheters
10/2014